COMMUNIQUÉS West-GlobeNewswire
-
ECM Therapeutics Reports Promising Results in Fistula Repair
13/10/2026 -
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
13/10/2026 -
Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026
13/10/2026 -
Alembic Therapeutics LLC Announces Availability of Clonidine Hydrochloride Tablets, 0.05mg
13/10/2026 -
Applied Biologics Announces First Patient Treated in Phase 3 BIOxHEAL™ Clinical Trial
13/10/2026 -
SafeSpace Global Appoints former Amazon, Google and YouTube Executive as Chief Operating Officer to Accelerate Next Phase of AI-Powered Growth
13/10/2026 -
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
13/10/2026 -
ProText Mobility Chairman Confirms 831.3 Million Common Shares in SEC Filing — Chairman and CEO Reaffirm Zero Preferred Conversions, Unified Management Philosophy and Shareholder Solidarity
13/10/2026 -
Acentra Health’s Chief Health and Informatics Officer Ryan Bosch, MD, FACP Named Fellow of the American College of Health Data Management
13/10/2026 -
Giraffe Bio raises $6.4M Seed to scale next-generation reagents for copper mining
13/10/2026 -
Stride Autism Centers Expands Early Intervention ABA Access with New Chicago Location
13/10/2026 -
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
13/10/2026 -
Johns Hopkins Health Plans Named Corporate Champion by The Tree House Child Advocacy Center
13/10/2026 -
Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156
13/10/2026 -
Opus Genetics to Present at the Chardan Annual Healthcare Conference
13/10/2026 -
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
13/10/2026 -
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
13/10/2026 -
ZoomRx Launches Marketing Asset Testing (MAT) on Sagan Agents, Bringing Continuous, Channel-Specific Asset Testing to Pharma Brand Teams
13/10/2026 -
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
13/10/2026
Pages